The rapid progress in COVID vaccine development and implementation

Alan D T Barrett¹, Richard W Titball², Paul A MacAry³, Richard E Rupp^{4

5}, Veronika von Messling⁶, David H Walker^{4

7}, Nicolas V J Fanget⁸

Affiliations

¹ Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA. abarrett@UTMB.EDU.
² College of Life and Environmental Sciences, University of Exeter, Devon, UK.
³ Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore (NUS), 5 Science Drive 2, Blk MD4, Level 3, Singapore, 117545, Singapore.
⁴ Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
⁵ Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.
⁶ Life Sciences Unit, Federal Ministry of Education and Research, Berlin, Germany.
⁷ Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
⁸ Nature Research, London, UK.

Editorial

Alan D T Barrett et al. NPJ Vaccines. 2022.

. 2022 Feb 10;7(1):20.

doi: 10.1038/s41541-022-00442-8.

Alan D T Barrett¹, Richard W Titball², Paul A MacAry³, Richard E Rupp^{4

5}, Veronika von Messling⁶, David H Walker^{4

7}, Nicolas V J Fanget⁸

¹ Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA. abarrett@UTMB.EDU.
² College of Life and Environmental Sciences, University of Exeter, Devon, UK.
³ Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore (NUS), 5 Science Drive 2, Blk MD4, Level 3, Singapore, 117545, Singapore.
⁴ Sealy Institute for Vaccine Sciences and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
⁵ Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, USA.
⁶ Life Sciences Unit, Federal Ministry of Education and Research, Berlin, Germany.
⁷ Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA.
⁸ Nature Research, London, UK.

No abstract available

Conflict of interest statement

A.D.T.B., R.W.T., P.A.M., R.E.R., V.v.M., and D.H.W. are editors of NPJ Vaccines.

1. Li Q, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New Engl. J. Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316. - DOI - PMC - PubMed
1. Wu F, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265–269. doi: 10.1038/s41586-020-2008-3. - DOI - PMC - PubMed
1. Medicines and Healthcare products Regulatory Agency. Regulatory approval of Pfizer/BioNTech vaccine for COVID-19. https://www.gov.uk/government/publications/regulatory-approval-of-pfizer... (Medicines and Healthcare products Regulatory Agency, 2020).
1. Shang W, Yang Y, Rao Y, Rao X. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines. 2020;5:18. doi: 10.1038/s41541-020-0170-0. - DOI - PMC - PubMed
1. Kleanthous H, et al. Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. NPJ Vaccines. 2021;6:128. doi: 10.1038/s41541-021-00393-6. - DOI - PMC - PubMed